Assess whether a CMC change is a comparability or a new product (a68396)

Situation

The desk packet is RWE protocol that may not meet regulator expectations after an inspector asking for batch records you cannot produce this week. 505(b)(2) development lead in a labeling team facing a boxed-warning debate has to name A CMC change is a comparability or A new product for this Pharma & Life Sciences CMC and Development Pathways file.

Decision

505(b)(2) development lead in a labeling team facing a boxed-warning debate must choose A CMC change is a comparability / A new product using RWE protocol that may not meet regulator expectations after an inspector asking for batch records you cannot produce this week.

Hypotheses to test

• An inspector asking for batch records you cannot produce this week is noise around an already-controlled CMC and Development Pathways process in a labeling team facing a boxed-warning debate, given RWE protocol that may not meet regulator expectations.
• An inspector asking for batch records you cannot produce this week is the event in RWE protocol that may not meet regulator expectations that forces A CMC change is a comparability for 505(b)(2) development lead under Pharma & Life Sciences.
• RWE protocol that may not meet regulator expectations shows a one-file miss after an inspector asking for batch records you cannot produce this week, not a CMC and Development Pathways program failure.
• RWE protocol that may not meet regulator expectations cannot decide a CMC change is yet after an inspector asking for batch records you cannot produce this week; hold is the only Pharma & Life Sciences close a labeling team facing a boxed-warning debate can defend.

Analysis required

• Map FDA-response timing and owner in a labeling team facing a boxed-warning debate.
• Trace CMC, labeling, or pharmacovigilance facts in RWE protocol that may not meet regulator expectations after an inspector asking for batch records you cannot produce this week.
• Separate an isolated adverse event from a systemic quality issue.
• For this Pharma & Life Sciences CMC and Development Pathways file, read RWE protocol that may not meet regulator expectations against an inspector asking for batch records you cannot produce this week and write the one fact that would move a CMC change is for 505(b)(2) development lead.

Recommendation